Why the study?
Does female sex influence alloreactivity, acute rejection, transplant-related coronary artery disease, and survival in primary cardiac allograft recipients?
Does female sex influence alloreactivity, acute rejection, transplant-related coronary artery disease, and survival in primary cardiac allograft recipients?
Female heart transplant recipients exhibit a higher risk of early allograft rejection and infection-related mortality, but a lower risk of late transplant-related coronary artery disease compared to males.
Answers are grounded in this paper and cite their sources.
May warrant sex-stratified early surveillance post-transplant; leaves open mechanisms of differential rejection and vasculopathy risks.
Background The influence of sex on alloreactivity and graft outcome after heart transplantation was evaluated. Methods and Results A retrospective review of 520 consecutive recipients of a primary cardiac allograft between 1992 and 2000 at a single center was performed. The influence of sex on alloreactivity, acute rejection, transplant-related coronary artery disease, and survival was determined. Statistical methods included logistic regression analysis and Kaplan-Meier actuarial survival analysis. Female recipients had an increased prevalence before transplant of idiopathic cardiomyopathy, antinuclear antibodies, and HLA-B8, DR3 haplotypes. After transplant, female sex predicted shorter duration to a first rejection, higher cumulative rejection frequency, and earlier posttransplant production of anti-HLA antibodies. Female recipients had higher early mortality rates (<6 months) that were due to infection. Fatal infections correlated with 2-fold higher cyclosporine levels in female recipients. However, the incidence of transplant-related coronary artery disease developing beyond 1 year after transplant was lower in female than in male recipients. Conclusions Females undergoing cardiac transplantation are more likely to manifest features of an underlying autoimmune state. This may predispose to a higher posttransplant risk of allograft rejection and requirement for increased immunosuppression. Earlier diagnosis and management of alloreactivity in female recipients before development of acute rejection and the use of more focused and less globally immunosuppressive agents during established rejections may have a significant effect on the clinical outcome of female cardiac allograft recipients.
No takes yet. Share an insight, caveat, or question.
Lietz et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: